10-Q: Zimmer Biomet Q2 Sales Up 7%, Earnings Decline on Acquisition Costs

Zimmer Biomet Holdings, Inc. reported a 7% increase in net sales for Q2 2025, driven by acquisitions and market growth, but net earnings significantly declined due to acquisition-related costs and higher interest expenses.

Summary

• Net sales for the three months ended June 30, 2025, increased by 7.0% to $2,077.3 million, compared to $1,942.0 million in the prior year period.
• Net sales for the six months ended June 30, 2025, increased by 4.0% to $3,986.4 million, compared to $3,831.2 million in the prior year period.
• Net earnings for the three months ended June 30, 2025, were $153.4 million, a decrease from $243.1 million in the same prior year period.
• Net earnings for the six months ended June 30, 2025, were $336.0 million, a decrease from $415.9 million in the same prior year period.
• Diluted earnings per common share for the three months ended June 30, 2025, were $0.77, down from $1.18 in the prior year period.
• Diluted earnings per common share for the six months ended June 30, 2025, were $1.68, down from $2.01 in the prior year period.
• The Paragon 28 acquisition, completed on April 21, 2025, contributed 2.6% to net sales growth in the three-month period and 1.4% in the six-month period.
• Foreign currency exchange rates had a positive effect of 1.6% on net sales in the three-month period and 0.1% in the six-month period.
• Operating profit for the three months ended June 30, 2025, was $300.0 million, down from $351.3 million in the prior year period.
• Operating profit for the six months ended June 30, 2025, was $592.3 million, down from $617.2 million in the prior year period.
• Acquisition, integration, divestiture and related expenses significantly increased to $78.9 million in Q2 2025 from $5.2 million in Q2 2024.
• Interest expense, net, increased to $79.3 million in Q2 2025 from $51.1 million in Q2 2024.
• The effective tax rate (ETR) for Q2 2025 was 31.7%, significantly higher than 19.6% in Q2 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company achieved strong revenue growth driven by strategic acquisitions in high-growth segments, profitability (net earnings and EPS) significantly declined due to substantial acquisition and integration costs, higher interest expenses, and an increased effective tax rate. The future outlook anticipates continued revenue growth but also continued pressure on net earnings, indicating a mixed financial performance with significant investments impacting short-term profitability.

Positives

• Strong net sales growth of 7.0% in Q2 2025 and 4.0% in H1 2025, driven by strategic acquisitions and market expansion.
• The acquisition of Paragon 28, a leader in foot and ankle orthopedics, significantly increased market share in a faster-growing segment.
• New product introductions and commercial execution contributed positively to volume and mix trends.
• Successful offsetting of negative pricing pressure through internal initiatives and passing on inflationary impacts to customers.
• Lower restructuring costs in the current period compared to the prior year due to the timing and completion of certain programs.
• Net cash provided by operating activities increased to $761.0 million in H1 2025 from $597.4 million in H1 2024, reflecting favorable timing of payments and lower bonus payments.
• Successful issuance of $1,748.1 million in new senior notes, strengthening the company's capital structure.
• New revolving credit facilities totaling $2.5 billion provide substantial liquidity and financial flexibility.

Negatives

• Significant decline in net earnings by 36.9% in Q2 2025 and 19.3% in H1 2025, primarily due to acquisition-related costs and higher interest expense.
• Diluted earnings per common share decreased by 34.7% in Q2 2025 and 16.4% in H1 2025.
• Operating profit decreased by 14.7% in Q2 2025 and 4.1% in H1 2025.
• Increased cost of products sold due to higher manufacturing costs from inflation and the selling of Paragon 28 inventory at its stepped-up fair value.
• Intangible asset amortization expense increased due to recent acquisitions.
• Selling, general and administrative (SG&A) expenses increased due to Paragon 28 expenses, direct-to-patient marketing investments, information technology, and medical education events.
• Higher net interest expense due to increased average debt balances and new borrowings at higher interest rates.
• The effective tax rate significantly increased to 31.7% in Q2 2025 and 25.9% in H1 2025, compared to 19.6% in the prior year periods, partly due to a change in assertion regarding indefinite reinvestment of foreign earnings.
• Decline in Technology & Data, Bone Cement and Surgical net sales due to lower sales of the ROSA Robot.

Risks

• Competition in the medical device industry.
• Ongoing pricing pressures from hospitals, health systems, and governmental healthcare cost containment efforts.
• Dependence on new product development, technological advances, and innovation.
• Changes in customer demand for products and services.
• Ability to attract, retain, develop, and maintain adequate succession plans for skilled employees, management, agents, and distributors.
• Risks and uncertainties related to successfully executing restructuring plans.
• Risks related to realizing anticipated benefits from the Paragon 28 acquisition, including integration challenges and maintaining business relationships.
• Effects of business disruptions affecting the company, suppliers, customers, or payors.
• Unplanned delays, disruptions, and expenses from enterprise resource planning and other system updates.
• Dependence on a limited number of suppliers for key raw materials and outsourced activities.
• Risk of disruptions in the supply of materials and components.
• Breaches or failures of information technology systems or products, including cyberattacks.
• Outcome of government investigations and legal proceedings, including product liability and intellectual property claims.
• Impact of healthcare reform and cost containment measures, including reductions in reimbursement levels.
• Impact of substantial indebtedness on the ability to service debt obligations and refinance at maturity.
• Changes in tax obligations from examinations by tax authorities and changes in tax laws, including those related to transfer pricing and foreign earnings.
• Risk of additional tax liability due to recategorization of independent agents and distributors to employees.
• Changes in tariffs relating to imports, with an anticipated $40 million in additional expenses in full year 2025.
• Risk of material impairment of goodwill and other intangible assets.
• Changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations.
• Domestic and international business impact of political, social, and economic instability, tariffs, trade restrictions, and conflicts.
• Challenges relating to changes in and compliance with governmental laws and regulations, including FDA regulations and healthcare fraud laws.
• Ability to remediate matters identified in inspectional observations by the FDA and other regulators.

Future Outlook

The company expects full-year 2025 revenue growth of 6.7% to 7.7%, with the Paragon 28 acquisition contributing 2.7% and foreign currency positively affecting sales by 0.5%. Net earnings are projected to decrease in 2025 compared to 2024 due to higher acquisition and integration costs, increased operating expenses, higher intangible asset amortization from the Paragon 28 acquisition, elevated manufacturing costs due to inflation and tariffs (approximately $40 million in additional expenses), higher net interest expense from increased borrowings and interest rates, and a higher estimated effective tax rate. These negative impacts are expected to be partially offset by higher net sales, leverage from fixed operating expenses, ongoing savings from restructuring plans, and lower employee termination and other charges from restructuring initiatives.

Management Comments

• Net sales growth was driven by a combination of the Paragon 28 acquisition, market growth, new product introductions, and commercial execution across the organization.
• The decreases in earnings were primarily due to costs related to the Paragon 28 acquisition, including acquisition-related costs and higher interest expense incurred for debt borrowed for the acquisition; higher cost of products sold due to sales volumes increases and higher manufacturing costs due to inflation; and investments made to direct-to-patient marketing and information technology.
• We expect 2025 full year-over-year revenue growth of 6.7 percent to 7.7 percent in 2025, driven by a combination of Paragon 28 net sales, market growth, new product introductions and commercial execution.
• We estimate net earnings will decrease in 2025 when compared to 2024 due to higher acquisition and integration costs, operating expenses and intangible asset amortization related to the Paragon 28 acquisition, higher manufacturing costs caused by inflation, tariffs, higher net interest expense due to higher interest rates and increased borrowings and a higher estimated effective tax rate due to favorable 2024 adjustments that are not expected to recur.
• We believe that cash flows from operations, our cash and cash equivalents on hand, and available borrowings under our revolving credit facilities will be sufficient to meet our ongoing liquidity requirements for at least the next twelve months.

Industry Context

The company operates in the global orthopedic and medical device market, which is influenced by demographic changes (e.g., aging populations driving demand for elective surgical procedures like knee and hip replacements). The acquisition of Paragon 28 positions the company in the faster-growing foot and ankle orthopedic segment, while the planned acquisition of Monogram Technologies aims to expand its portfolio in the orthopedic robotics market, aligning with the broader industry trend towards digital and AI-driven surgical technologies. The industry also faces ongoing pricing pressures from healthcare systems and governmental cost containment efforts, as well as challenges from inflation and tariffs.

Comparison to Industry Standards

• The company's acquisition of Paragon 28, a leading medical device company focused exclusively on the foot and ankle orthopedic segment, aligns with a strategy to increase market share in a segment growing faster than some other orthopedic areas.
• The planned acquisition of Monogram Technologies, an orthopedic robotics company, is a strategic move to enhance the company's suite of orthopedic robotics, enabling solutions, and analytics, reflecting a broader industry trend towards advanced surgical guidance and AI integration.
• The company's efforts to offset negative pricing pressure through internal initiatives and passing on inflationary impacts to customers demonstrate adaptability in a challenging healthcare cost environment, a common challenge for medical device manufacturers globally.

Corporate Governance

Legal Proceedings

• Involvement in various legal proceedings, including product liability claims related to Durom Cup, Zimmer M/L Taper, M/L Taper with Kinectiv Technology, Versys Femoral Head, and M2a-Magnum hip system.
• Disputes with the IRS regarding proposed adjustments for tax years 2013-2015 (transfer pricing) and 2016-2019 (U.S. taxation of foreign earnings, potentially resulting in an additional $312 million tax expense). The company intends to vigorously contest these adjustments.
• Accrued litigation liabilities were $156.8 million as of June 30, 2025.
• Succeeded to Paragon 28's existing litigation matters as a result of the acquisition, with immaterial liabilities recognized.

Stakeholder Impact

• **Shareholders**: Impacted by decreased net earnings and diluted EPS, but also by strategic acquisitions aimed at long-term growth and ongoing share repurchase program. Dividends continue to be paid.
• **Employees**: Affected by ongoing restructuring plans (2025, 2023, 2019) which involve employee termination benefits, but also by investments in technology and new product development.
• **Customers**: Benefit from expanded product portfolio, particularly in foot and ankle orthopedics and future robotic technologies, and improved service from distributor acquisitions.
• **Suppliers**: Potential impact from cost reduction initiatives and changes in manufacturing footprint due to restructuring plans.
• **Creditors**: Affected by increased debt balances due to recent acquisitions and new debt issuances, but the company maintains compliance with debt covenants and has significant available credit facilities.

Next Steps

• Complete the closure of a manufacturing facility under the 2019 Restructuring Plan in 2025.
• Continue to realize gross annual pre-tax operating expense reductions of $175 million to $200 million from the 2023 Restructuring Plan by the end of 2025.
• Continue to realize gross annual pre-tax operating expense reductions of approximately $95 million from the 2025 Restructuring Plan by the end of 2027.
• Finalize the purchase price allocation for the Paragon 28 acquisition no later than one year after the acquisition date.
• Finalize the purchase price allocation for the OrthoGrid acquisition no later than one year after the acquisition date.
• Close the acquisition of Monogram Technologies Inc. in the second half of 2025, subject to regulatory approvals and Monogram's common stockholder approval.
• Continue to vigorously contest proposed IRS adjustments for tax years 2013-2015 and 2016-2019.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial statements and disclosures.
• Continue paying quarterly cash dividends, subject to Board of Directors' approval.
• Continue share repurchases under the authorized $2.0 billion program.

Key Dates

Recommendation

Zimmer Biomet's Q2 2025 results present a mixed picture, warranting a 'hold' recommendation. While the company demonstrates robust top-line growth driven by strategic acquisitions like Paragon 28 and a strong pipeline in high-growth areas such as foot & ankle and robotics, profitability has significantly declined. The substantial increase in acquisition-related costs, higher interest expenses from increased debt, and a higher effective tax rate have compressed net earnings and EPS. The ongoing IRS tax disputes add a layer of uncertainty regarding future financial obligations. Although the company is actively managing costs through restructuring and has strong liquidity, the short-term earnings pressure and integration risks associated with recent and planned acquisitions suggest that the benefits of these strategic moves may take time to materialize. Investors should monitor the successful integration of acquired assets, the realization of restructuring savings, and the resolution of tax disputes before considering a more aggressive stance.

Keywords

Orthopedics, Medical Devices, Joint Replacement, Knees, Hips, Sports Medicine, Extremities, Trauma, Craniomaxillofacial, Thoracic, Surgical Robotics, AI Surgical Guidance, SEC Filing, 10-Q, Financial Results, Acquisition, Restructuring, Debt, Earnings, Revenue